Ascentage Broadens Horizons As Pipeline Shows Renewed Promise
New Bcl-2 Inhibitor Data At ASCO
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
